Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5691)
All Articles published online
|
Publishing Process of This Article
|
Sep 27, 2014 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676 [PMID: 25276283 DOI: 10.4254/wjh.v6.i9.670] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i9/670.htm |
| Number | Citing Articles |
| 1 |
Philip R. Cohen. Sorafenib-Associated Facial Acneiform Eruption. Dermatology and Therapy 2015; 5(1): 77 doi: 10.1007/s13555-014-0067-9
|
| 2 |
Lorenza Rimassa, Romano Danesi, Tiziana Pressiani, Philippe Merle. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treatment Reviews 2019; 77: 20 doi: 10.1016/j.ctrv.2019.05.004
|
| 3 |
Giulia Rovesti, Giulia Orsi, Andrikou Kalliopi, Caterina Vivaldi, Giorgia Marisi, Luca Faloppi, Francesco Giuseppe Foschi, Nicola Silvestris, Irene Pecora, Giuseppe Aprile, Eleonora Molinaro, Laura Riggi, Paola Ulivi, Matteo Canale, Alessandro Cucchetti, Emiliano Tamburini, Giorgio Ercolani, Lorenzo Fornaro, Pietro Andreone, Patrizia Zavattari, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors 2019; 6(3-4): 92 doi: 10.1159/000502714
|
| 4 |
Omar Abdel-Rahman, Angela Lamarca. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Review of Gastroenterology & Hepatology 2017; 11(1): 75 doi: 10.1080/17474124.2017.1264874
|
| 5 |
Helder Cardoso, Ana Margarida Alves, Margarida Marques, Ana Maria Vale, Pedro Pereira, Guilherme Macedo. Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. GE Portuguese Journal of Gastroenterology 2016; 23(5): 243 doi: 10.1016/j.jpge.2016.04.006
|
| 6 |
Colleen S. Schwartz. Plantar Erythrodysesthesia from Oral Targeted Cancer Treatment: A Case Report. Journal of the American Podiatric Medical Association 2022; 112(4) doi: 10.7547/20-268
|
| 7 |
Masanori Ochi, Toshiro Kamoshida, Atsushi Ohkawara, Haruka Ohkawara, Nobushige Kakinoki, Shinji Hirai, Akinori Yanaka. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. World Journal of Gastroenterology 2018; 24(28): 3155-3162 doi: 10.3748/wjg.v24.i28.3155
|
| 8 |
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, Caterina Vivaldi, Oronzo Brunetti, Luca Ielasi, Fabio Conti, Giulia Rovesti, Laura Gramantieri, Mario Domenico Rizzato, Irene Pecora, Antonella Argentiero, Federica Teglia, Sara Lonardi, Francesca Salani, Alessandro Granito, Vittorina Zagonel, Giorgia Marisi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Francesca Benevento, Alessandro Cucchetti, Fabio Piscaglia, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology 2020; 15(6): 773 doi: 10.1007/s11523-020-00757-3
|
| 9 |
Penghui He, Haifeng Wan, Juan Wan, Hanyu Jiang, Yu Yang, Kunlin Xie, Hong Wu. Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1015527
|
| 10 |
Adélia Simão. Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib. GE Portuguese Journal of Gastroenterology 2016; 23(5): 231 doi: 10.1016/j.jpge.2016.08.001
|
| 11 |
Wenjun Wang, Wei Bai, Enxin Wang, Yan Zhao, Lei Liu, Man Yang, Hongwei Cai, Dongdong Xia, Lei Zhang, Jing Niu, Zhanxin Yin, Zhuoli Zhang, Daiming Fan, Jielai Xia, Guohong Han. mRECIST response combined with sorafenib‐related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. International Journal of Cancer 2017; 140(2): 390 doi: 10.1002/ijc.30451
|
| 12 |
Masako Shomura, Tatehiro Kagawa, Haruka Okabe, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Sachiko Takahira, Tetsuya Mine. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2908-7
|
| 13 |
Masanori Ochi, Toshiro Kamoshida, Masahiro Araki, Tadashi Ikegami. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. World Journal of Gastroenterology 2021; 27(32): 5424-5437 doi: 10.3748/wjg.v27.i32.5424
Abstract(553) |
Core Tip(401) |
Full Article(HTML)(1824)
|
Full Article (PDF)-7874K(287)
|
Full Article (Word)-263K(109)
|
Audio-1057K(2)
|
Peer-Review Report-197K(97)
|
Answering Reviewers-218K(95)
|
Times Cited (0)
|
Total Visits (6421)
|
Open
|
| 14 |
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Taizo Yamaguchi, Satoshi Itano, Hideya Suga, Takashi Niizeki, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Takumi Kawaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura. Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-21528-2
|
| 15 |
Alessandro Granito, Sara Marinelli, Giulia Negrini, Saverio Menetti, Francesca Benevento, Luigi Bolondi. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therapeutic Advances in Gastroenterology 2016; 9(2): 240 doi: 10.1177/1756283X15618129
|
| 16 |
Ping Wang, Gang Tan, Mingxin Zhu, Weidong Li, Bo Zhai, Xueying Sun. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2018; 12(1): 1 doi: 10.1080/17474124.2017.1373018
|
| 17 |
Masako Shomura, Haruka Okabe, Emi Sato, Kota Fukai, Koichi Shiraishi, Shunji Hirose, Kota Tsuruya, Yoshitaka Arase, Kazuya Anzai, Tatehiro Kagawa. Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers 2020; 12(11): 3078 doi: 10.3390/cancers12113078
|
| 18 |
Takuji Okusaka, Taiga Otsuka, Hideki Ueno, Shuichi Mitsunaga, Rie Sugimoto, Kei Muro, Isao Saito, Yusuke Tadayasu, Kohei Inoue, Arsene‐Bienvenu Loembé, Masafumi Ikeda. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Science 2016; 107(12): 1791 doi: 10.1111/cas.13077
|
| 19 |
R. Diaz-Beveridge, G. Bruixola, D. Lorente, J. Caballero, E. Rodrigo, Á. Segura, D. Akhoundova, A. Giménez, J. Aparicio. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clinical and Translational Oncology 2018; 20(3): 322 doi: 10.1007/s12094-017-1720-4
|
| 20 |
Daniel Kelly, Paz Fernández-Ortega, Eugenia Trigoso Arjona, Bruno Daniele. The role of nursing in the management of patients with renal and hepatic cancers: A systematic literature review. European Journal of Oncology Nursing 2021; 55: 102043 doi: 10.1016/j.ejon.2021.102043
|
| 21 |
Álvaro Díaz‐González, Marco Sanduzzi‐Zamparelli, Víctor Sapena, Ferran Torres, Neus LLarch, Gemma Iserte, Alejandro Forner, Leonardo da Fonseca, José Ríos, Jordi Bruix, María Reig. Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology & Therapeutics 2019; 49(5): 482 doi: 10.1111/apt.15088
|
| 22 |
Warit Ruanglertboon, Michael J. Sorich, Andrew Rowland, Ashley M. Hopkins. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. International Journal of Clinical Oncology 2020; 25(9): 1672 doi: 10.1007/s10147-020-01698-7
|
| 23 |
Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao-Ping Chen, Lucy Dagher, Junji Furuse, Jean-Francois H. Geschwind, Laura Ladrón de Guevara, Christos Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of Hepatology 2016; 65(6): 1140 doi: 10.1016/j.jhep.2016.07.020
|
| 24 |
Mohamed Bouattour, Audrey Payancé, Johanna Wassermann. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology 2015; 7(20): 2245-2263 doi: 10.4254/wjh.v7.i20.2245
|
| 25 |
Adam Doyle, Philip Marsh, Raghubinder Gill, Marcia Rodov, Waled Mohsen, Poornima Varma, Thai Hong, Simone I. Strasser, Sally Bell, Marno Ryan, Amanda Nicoll, John Lubel, Paul J. Gow, Michael Anthony Fink, Stuart Roberts, William Kemp, Ian Kronborg, Niranjan Arachchi, Virginia Knight, Anouk Dev. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scandinavian Journal of Gastroenterology 2016; 51(8): 979 doi: 10.3109/00365521.2016.1166518
|
| 26 |
Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi, Francesco Giuseppe Foschi, Mario Scartozzi, Rocco Granata, Luca Faloppi, Stefano Cascinu, Nicola Silvestris, Oronzo Brunetti, Vincenzo Ostilio Palmieri, Giorgio Ercolani, Raffaella Tortora. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology 2017; 12(6): 795 doi: 10.1007/s11523-017-0522-5
|
| 27 |
Aminah Jatoi, Fang-Shu Ou, Daniel H. Ahn, Tyler J. Zemla, Jennifer G. Le-Rademacher, Patrick Boland, Kristen K. Ciombor, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz-Josef Lenz, Jeff A. Sloan, Axel Grothey, Mario E. Lacouture, Tanios Bekaii-Saab. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. The Oncologist 2021; 26(7): 610 doi: 10.1002/onco.13730
|
| 28 |
Ninzi Tian, Dong Wu, Ming Tang, Huichuan Sun, Yuan Ji, Cheng Huang, Lingli Chen, Gang Chen, Mengsu Zeng. RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients. Open Medicine 2020; 15(1): 167 doi: 10.1515/med-2020-0024
|
| 29 |
Robert J Cersosimo. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. American Journal of Health-System Pharmacy 2021; 78(3): 187 doi: 10.1093/ajhp/zxaa365
|